NBIX
Neurocrine Biosciences Inc
NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$131.23
+2.43% today
Updated 2026-04-29
Market cap
$13.20B
P/E ratio
28.10
P/S ratio
4.61x
EPS (TTM)
$4.67
Dividend yield
—
52W range
$108 – $160
Volume
1.1M
WallStSmart proprietary scores
75
out of 100
Grade: B+
Buy
Investment rating
9.3
Growth
A+8.5
Quality
A8.5
Profitability
A7.0
Valuation
B+3/9
Piotroski F-Score
Weak
3.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$185.65
+41.47%
12-Month target
$131.76
+0.40%
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy20 Buy4 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.08 — safe zone
+ Free cash flow $386.00M — positive
+ Revenue growth 28.30% QoQ
+ Debt/equity 0.13x — low leverage
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.49B | $1.89B | $2.36B | $2.86B | $2.86B |
| Net income | $154.50M | $249.70M | $341.30M | $478.60M | $153.70M |
| EPS | — | — | — | — | $4.67 |
| Free cash flow | $322.90M | $361.60M | $557.20M | $748.70M | $386.00M |
| Profit margin | 10.38% | 13.23% | 14.49% | 16.73% | 16.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-04 | ABERNETHY, MATT | Sale | 2,249 | — |
| 2026-02-20 | ONYIA, JUDE | Sale | 3,110 | — |
| 2026-02-13 | ONYIA, JUDE | Buy | 55,119 | — |
Peer comparison
Smart narrative
Neurocrine Biosciences Inc trades at $131.23. representing a P/E of 28.10x trailing earnings. Our Smart Value Score of 75/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.08, it sits in the safe zone. TTM revenue stands at $2.86B. with profit margins at 16.70%.
Frequently asked questions
What is Neurocrine Biosciences Inc's stock price?
Neurocrine Biosciences Inc (NBIX) trades at $131.23.
Is Neurocrine Biosciences Inc overvalued?
Smart Value Score 75/100 (Grade B+, Buy).
What is the price target of Neurocrine Biosciences Inc (NBIX)?
The analyst target price is $185.65, representing +41.5% upside from the current price of $131.23.
What is Neurocrine Biosciences Inc's revenue?
TTM revenue is $2.86B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.08 — safe zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.61x
ROE16.40%
Beta0.35
50D MA$130.15
200D MA$137.33
Shares out0.10B
Float0.10B
Short ratio—
Avg volume1.1M
Performance
1 week+0.80%
1 month-0.39%
3 months-4.88%
YTD-7.47%
1 year—
3 years—
5 years—